


Quantitative Single Gene Report

Patient/ID: PATIENT, SAMPLE
Gender: Female
Date of Birth: 01-Jan-1950

Report Number: OR000123456-3052
Specimen Received: 22-Dec-2017
Date Reported: 04-Jan-2018

The Oncotype DX[®] test uses RT-PCR to determine the RNA expression of the genes below. These results may differ from estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) results reported using other methods or reported by other laboratories.¹ The ER, PR, and HER2 Scores are also included in the calculation of the Recurrence Score result.

ER Score = 9.3 Positive




The ER Score positive/negative cut-off of 6.5 units was validated from a study of 761 samples using the 1D5 antibody (immunohistochemistry) and 607 samples using the SP1 antibody (immunohistochemistry). The standard deviation for the ER Score is less than 0.5 units.²

Clinical Experience:


For ER+ breast cancer, the magnitude of tamoxifen benefit increases as the ER Score increases from 6.5 to ≥12.5.³ Please note: The Average Risk of Distant Recurrence reported on Page 1 based on the Recurrence Score result was determined in patients who received 5 years of tamoxifen treatment and takes into account the magnitude of tamoxifen benefit indicated by the ER Score.

PR Score = 7.1 Positive



The PR Score positive/negative cut-off of 5.5 units was validated from a study of 761 samples using the PR636 antibody (immunohistochemistry) and another study of 607 samples using the PR636 antibody (immunohistochemistry). The standard deviation for the PR Score is less than 0.5 units.²

HER2 Score = 8.0 Negative



The HER2 positive cut-off of ≥ 11.5 units, equivocal range from 10.7 to 11.4 units, and negative cut-off of <10.7 units were validated from concordance studies of 755 samples using the Herceptin[™] assay (immunohistochemistry) and another study of 568 samples using the PathVysion[®] assay (FISH). The standard deviation for the HER2 score is less than 0.5 units.⁴

References:
1. ER Score based on quantitative ER expression (estrogen receptor); PR Score based on quantitative PGR expression (progesterone receptor); HER2 Score based on quantitative ERBB2 expression.
2. Badve et al. J Clin Oncol. 2007; Baehner et al. ASCO Breast 2007. Abstract 88.
3. Kim et al. J Clin Oncol, 2011.
4. Baehner et al. J Clin Oncol. 2010. and Baehner et al. ASCO Breast 2007. Abstract 41.

Laboratory Director(s): S. Shak, MD; F. Baehner, MD; H. Bailey, MD & P. Joseph, MD

This test was developed and its performance characteristics determined by Genomic Health, Inc. It has not been cleared or approved by the FDA, nor is it currently required to be. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.